Dr. Reddy’s settles dispute with Indivior, to receive $72m

A view of Dr. Reddy’s Laboratories Ltd. campus in Hyderabad. File photo

A view of Dr. Reddy’s Laboratories Ltd. campus in Hyderabad. File photo

Pharma major Dr. Reddy’s Laboratories has entered into settlement agreement with British drugmaker Indivior resolving patent litigation relating to latter's opioid dependence treatment drug Suboxone.

The company has entered into a settlement agreement with Indivior Inc, Indivior UK Limited and Aquestive Therapeutics Inc following which it will receive payments totalling $72 million by March 31, 2024, Dr. Reddy’s said on Friday.

The agreement resolves all claims between the parties relating to Dr. Reddy’s generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages; Indivior's and Aquestive's patent infringement allegations and the company's antitrust counterclaims.

As part of the settlement, the underlying litigation will be dismissed, the Hyderabad-headquartered drugmaker said.

Our code of editorial values

  1. Comments will be moderated by The Hindu editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.

Printable version | Jun 25, 2022 10:44:05 am |